“There is real bipartisan unease around consolidation and lack of transparency in the system,” he said. “All those things could get thrown into the conversation in a way that many on Wall Street may not be expecting.” 

While investors are probably right to assume some easing up of regulatory scrutiny under Trump, they shouldn’t expect a total letup. There is at least some support on both sides of the aisle to tackle the myriad problems with America’s healthcare system, says Andrew Schwab, founder of Washington-based Platform Government Strategies. 

“There is real bipartisan unease around consolidation and lack of transparency in the system,” he said. “All those things could get thrown into the conversation in a way that many on Wall Street may not be expecting.”